BOTHELL, Wash.--(BUSINESS WIRE)--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management
will present at the Bank of America Merrill Lynch 2012 Health Care
Conference on Tuesday, May 15, 2012 at 1:00 p.m. Pacific Time. The
presentation will be webcast live and available for replay from Seattle
Genetics' website at www.seattlegenetics.com
in the Investors
and News section.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. The U.S. Food and Drug Administration granted
accelerated approval of ADCETRIS in August 2011 for two indications.
ADCETRIS is being developed in collaboration with Millennium: The Takeda
Oncology Company. In addition, Seattle Genetics has three other
clinical-stage antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME
and ASG-22ME. Seattle Genetics has collaborations for its ADC technology
with a number of leading biotechnology and pharmaceutical companies,
including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo,
Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as
ADC co-development agreements with Agensys, an affiliate of Astellas,
and Genmab. More information can be found at www.seattlegenetics.com.
